Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Persistent viral replication increases the risk of progression to liver cirrhosis, development of hepatocellular carcinoma (HCC) and liver-related death [2-4]. [...]the goals of antiviral therapy are to improve quality of life and survival by preventing progression of the disease to cirrhosis, HCC and death [5,6]. [...]in this study, there was no TDF monotherapy group because TDF monotherapy and TDF+NAs combination therapy did not show any difference in VR in NA-experienced patients (Table 1). ADV monotherapy in patients with LAM resistance increase the risk of drug resistance [17-19]. [...]there is a concern about selective pressure on pre-existing resistant mutant viruses [32]. [...]considering the result from current study [30] and previous studies [23-26,31], TDF with or without NAs might be very effective to treat the patient with suboptimal response to ADV-based therapy.